Incyte, Genentech Partner in Immunotherapies
Incyte Corporation has entered into a clinical trial agreement with Genentech to evaluate the safety, tolerability, and preliminary efficacy of Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, in combination with Genentech's PD-L1 immune checkpoint inhibitor, MPDL3280A, in patients with non-small cell lung cancer (NSCLC).
Under the terms of the collaboration,
Both INCB24360 and MPDL3280A are part of a new class of cancer treatments known as immunotherapies that are designed to enhance the body's own defenses in fighting cancer; both agents target distinct regulatory components of the immune system. INCB24360 is an orally bioavailable small molecule inhibitor of IDO1 that has nanomolar potency in both biochemical and cellular assays, potent activity in enhancing T lymphocyte, dendritic cell and natural killer cell responses in vitro, with a high degree of selectivity. MPDL3280A (also known as an anti-PDL1) is an investigational monoclonal antibody designed to interfere with a protein called PD-L1 (Programmed Death-Ligand 1). MPDL3280A is designed to make cancer cells more vulnerable to the body's own immune system by interfering with PD-L1. PD-L1 is expressed on tumor cells and tumor-infiltrating immune cells, preventing them from binding to two receptors, PD-1 and B7.1, on the surface of T cells. By inhibiting PD-L1, MPDL3280A may enable the activation of T cells, restoring their ability to effectively detect and attack tumor cells.
Source: Incyte Corporation